Merck KGaA Eyes Rare‑Disease Growth With $20/ADS Purchase of Silence Therapeutics
Merck KGaA’s $20‑per‑ADS takeover of UK biotech Silence Therapeutics boosts its rare‑disease RNAi lineup with Divesiran, offering a 25%+ IRR and U.K. market access strategy.
4 minutes to read

